Search hospitals

>

South Carolina

>

Spartanburg

Spartanburg Medical Center

Claim this profile

Spartanburg, South Carolina 29303

Global Leader in Breast Cancer

Global Leader in Lung Cancer

Conducts research for Breast cancer

Conducts research for Non-Small Cell Lung Cancer

Conducts research for Ovarian Cancer

319 reported clinical trials

15 medical researchers

Photo of Spartanburg Medical Center in SpartanburgPhoto of Spartanburg Medical Center in SpartanburgPhoto of Spartanburg Medical Center in Spartanburg

Summary

Spartanburg Medical Center is a medical facility located in Spartanburg, South Carolina. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Ovarian Cancer and other specialties. Spartanburg Medical Center is involved with conducting 319 clinical trials across 437 conditions. There are 15 research doctors associated with this hospital, such as Michael Humeniuk, Amarinthia (Amy) Curtis, Vikas Dembla, and Jeremy M. Kilburn.

Area of expertise

1

Breast Cancer

Global Leader

Spartanburg Medical Center has run 65 trials for Breast Cancer. Some of their research focus areas include:

HER2 negative
ER positive
Stage IV
2

Lung Cancer

Global Leader

Spartanburg Medical Center has run 52 trials for Lung Cancer. Some of their research focus areas include:

Stage II
Stage IV
Stage I

Top PIs

Clinical Trials running at Spartanburg Medical Center

Lung Cancer

Breast Cancer

Ovarian Cancer

Colorectal Cancer

Prostate Cancer

Bladder Cancer

Melanoma

Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Pancreatic Cancer

Image of trial facility.

High-Dose Radiation + Chemotherapy and Immunotherapy

for Non-Small Cell Lung Cancer

This trial tests whether adding a precise form of radiation therapy to the usual treatment improves outcomes for patients with advanced lung cancer that can't be operated on. The goal is to see if this combination helps patients live longer and prevents cancer from worsening. This form of radiation therapy has shown promise in improving survival rates in patients with various stages of lung cancer.

Recruiting

2 awards

Phase 3

14 criteria

Image of trial facility.

Treatment Timing

for Non-Small Cell Lung Cancer

This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.

Recruiting

2 awards

Phase 3

4 criteria

Image of trial facility.

Immunotherapy + Chemotherapy

for Non-Small Cell Lung Cancer

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.

Recruiting

2 awards

Phase 3

27 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Spartanburg Medical Center?

Where is Spartanburg Medical Center located?

Who should I call to ask about financial aid or insurance network?

What insurance does Spartanburg Medical Center accept?

What awards or recognition has Spartanburg Medical Center received?